Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Pronorvistaon Jun 04, 2021 7:45am

205 Views

Post# 33328229

ATE

Antibe Therapeutics Inc

TSX:ATEposition sur OTCQX International

en date du 2021-06-04 Le 07:43 HE
Actualiser
Imprimer

Dernier cours $
3,97
Variation du jour (%)

0,00 (0,00%)

Cours achet. / Lots
4,00/ 3
Cours vend. / Lots
4,00/ 1
Ouvert / Clt. prc.
0,00 / 3,97
Fourchette du jour
---
Fourchette de 52 sem.

Bas3,05

Haut7,52
Volume
---

Cours cible linkCaret icon

Conseil des experts linkCaret icon

17,69$

(+345.54% Hausse)

Selon l’valuation de 2 analystes reconnus proposant des cours cibles sur 12 mois pour ATBPF au cours des 3 derniers mois, le cours cible moyen est de 17,69$ (cours estim suprieur de 19,38$ et cours estim infrieur de 16,00$).

High

19,38$

Low

16,00$

Average

17,69$

Past 12 months ratings
Week Ending	Consensus Rating	Buy Ratings
06/05/20	Achat	1
06/12/20	Achat	1
06/19/20	Achat	1
06/26/20	Achat	1
07/03/20	Achat	1
07/10/20	Achat	1
07/17/20	Achat	2
07/24/20	Achat	2
07/31/20	Achat	2
08/07/20	Achat	2
08/14/20	Achat	2
08/21/20	Achat	3
08/28/20	Achat	3
09/04/20	Achat	3
09/11/20	Achat	3
09/18/20	Achat	3
09/25/20	Achat	4
10/02/20	Achat	4
10/09/20	Achat	4
10/16/20	Achat	3
10/23/20	Achat	3
10/30/20	Achat	3
11/06/20	Achat	3
11/13/20	Achat	3
11/20/20	Achat	3
11/27/20	Achat	2
12/04/20	Achat	3
12/11/20	Achat	3
12/18/20	Achat	3
12/25/20	Achat	2
01/01/21	Achat	2
01/08/21	Achat	2
01/15/21	Achat	2
01/22/21	Achat	3
01/29/21	Achat	4
02/05/21	Achat	4
02/12/21	Achat	4
02/19/21	Achat	4
02/26/21	Achat	4
03/05/21	Achat	3
03/12/21	Achat	3
03/19/21	Achat	3
03/26/21	Achat	3
04/02/21	Achat	3
04/09/21	Achat	3
04/16/21	Achat	3
04/23/21	Achat	3
04/30/21	Achat	3
05/07/21	Achat	3
05/14/21	Achat	2
05/21/21	Achat	2
05/28/21	Achat	1
06/04/21	Achat	1

Next 12 months price targets
Target Name	Price Target
High	19,38$
Low	16,00$
Average	17,69$

Analyst Ratings

Vente 0

Conservation 0

Achat 2

2 cotes | Globale: Achat linkCaret icon

Achat 100%
Conservation 0%
Vente 0%

Selon 2 cotes attribues ATBPF par des analystes ces 3 derniers mois, la cote globale est de Achat

DTAIL DES COTES DE L’ANALYSTE linkCaret icon

VOIR TOUS LES ANALYSTES SUIVIS

Analyst Ratings
DATE	NOTE	MESURE	ANALYST NAME	COURS CIBLE
05.18.21	Achat	Amorc	KEMP DOLLIVER Brookline Capital Markets null star rating	19,38$
05.06.21	Achat	Ritre	STEFAN QUENNEVILLE Echelon Wealth Partners 1.8 star rating	16,00$
02.24.21	Achat	Maintenu	TANIA GONSALVES Canaccord Genuity 4.6 star rating	14,50$
02.09.21	Achat	Maintenu	JASON MCCARTHY Maxim Group 4.9 star rating	10,00$